Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07405476 · ClinicalTrials.gov registry record · Phase 2
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
A Phase 2 study, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT07405476 is a Phase 2 study that is actively recruiting participants, run by Emory University. The registered enrollment target is 38 participants.
The verdict
NCT07405476, a Phase 2 study, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Interventions
- PROCEDURE Echocardiography Test
- PROCEDURE Resection
- PROCEDURE Multigated Acquisition Scan
- OTHER Patient Observation
- BIOLOGICAL Zanidatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-04-07 |
| Est. Completion | 2029-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07405476
The ClinicalTrials.gov registry entry for NCT07405476 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Echocardiography Test is the first listed.
NCT07405476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07405476 about?
NCT07405476 is a clinical study titled "Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment". This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that ma...
What is the current status of trial NCT07405476?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2026-04-07. Estimated completion is 2029-12-18.
What interventions are being tested in trial NCT07405476?
The interventions under investigation include: Echocardiography Test (PROCEDURE), Resection (PROCEDURE), Multigated Acquisition Scan (PROCEDURE), Patient Observation (OTHER), Zanidatamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07405476?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.